Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Coniine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.44 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.44 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.44 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.44 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.44 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.44 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.35 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Coniine SCHEMBL25732 | 1.00 | CYP2D6 (0.44) | CYP2D6KMT2ACYP1A2MEN1LMNA | |
| Coniine SCHEMBL335908 | 0.98 | — | — | |
| Coniine SCHEMBL13596004 | 0.98 | — | — | |
| Coniine SCHEMBL96923 | 0.98 | — | — | |
| Coniine SCHEMBL25355 | 0.95 | CYP2D6 (0.44) | CYP2D6KMT2ACYP1A2MEN1LMNA | |
| Coniine SCHEMBL18707305 | 0.95 | CYP2D6 (0.44) | CYP2D6KMT2ACYP1A2MEN1LMNA | |
| SCHEMBL28301308 | 0.95 | CYP2D6 (0.48) | CYP2D6KMT2ACYP1A2MEN1LMNA | |
| Coniine SCHEMBL25356 | 0.95 | CYP2D6 (0.44) | CYP2D6KMT2ACYP1A2MEN1LMNA | |
| SCHEMBL22455184 | 0.95 | CYP2D6 (0.48) | CYP2D6KMT2ACYP1A2MEN1LMNA | |
| Coniine SCHEMBL27576046 | 0.95 | CYP2D6 (0.44) | CYP2D6KMT2ACYP1A2MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879578-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2009-05-13 | — | — | EP | claimed |
| EP-1879578-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV Pharmaceutical Inc. (US) | 2008-01-23 | — | — | EP | claimed |
| WO-2006102029-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2006-12-07 | — | — | WO | claimed |
| WO-2006102029-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-4168092-B1 | BALLOON CATHETER WITH PRECISION DRUG-ELUTING CAPABILITY | BARD INC C R (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| US-12472241-B2 | Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12458392-B2 | Scoring balloon with translating scoring wires | C.R. BARD, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12167883-B2 | Medical device including expandable muscle polymer | BARD PERIPHERAL VASCULAR, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| EP-4210606-B1 | MEDICAL DEVICE INCLUDING EXPANDABLE MUSCLE POLYMER | BARD PERIPHERAL VASCULAR INC (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-3970643-B1 | SCORING BALLOON WITH TRANSLATING SCORING WIRES | BARD INC C R (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-1178699-C | Pharmaceutical Compsns. contg. compounds with activity for enhancement of absorption of active ingredients | — | 2004-12-08 | — | — | CN | disclosed |
| WO-2004096096-A1 | DRUG-LOADED MEDICAL DEVICE | SCIMED LIFE SYSTEMS, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040215169-A1 | Drug-loaded medical device | SCIMED LIFE SYSTEMS, INC. (US) | 2004-10-28 | — | — | US | disclosed |
| US-20040073234-A1 | Medical implant | BOSTON SCIENTIFIC SCIMED, INC. | 2004-04-15 | — | — | US | disclosed |
| WO-2004016180-A2 | MEDICAL IMPLANT | BOSTON SCIENTIFIC LIMITED (BB) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004011055-A2 | IMPLANTABLE OR INSERTABLE MEDICAL DEVICES FOR CONTROLLED DRUG DELIVERY | SCIMED LIFE SYSTEMS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20030224033-A1 | Implantable or insertable medical devices for controlled drug delivery | BOSTON SCIENTIFIC SCIMED, INC. | 2003-12-04 | — | — | US | disclosed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097102-A1 | Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors | ALOX15, ALOX15B, ALOX5 | HTR1A 1610/4885CHRM2 4475/4885ADRA2A 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.